FindTrial
Sign In

Exploration on the Clinical Efficacy Evaluation of In-Hospital Preparation "Shanggan Mixture" in Treating Pediatric Rutter (Lung-Stomach Heat Blazing Syndrome) and Its Impact on Inflammatory Indicators Based on the Toxin-Heat Theory

"Shanggan Mixture" in Treating Pediatric Rutter (Lung-Stomach Heat Blazing Syndrome) and Its Impact on Inflammatory Indicators Based on the Toxin-Heat Theory

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000080
Enrollment
Unknown
Registered
2026-01-17
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Suppurative Tonsillitis

Interventions

Study Group:The study group was treated with Shanggan Mixture in combination with the conventional antibiotic anti-infection therapy applied to the control group
control group:The control group was routinely treated with antibiotics for anti-infection therapy

Sponsors

Huai'an Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the TCM diagnostic criteria and Western medicine diagnostic criteria for infantile tonsillitis (Erzi Rutou in TCM);(2) Aged 3–14 years old, regardless of gender; and being able to cooperate with the treatment;(3) Onset time = 48 hours;(4) Blood test indicating bacterial infection, with white blood cell (WBC) count ranging from 12,000 to 20,000/µL, or abnormal neutrophil percentage (N%) or C-reactive protein (CRP) level;(5) Complete medical records, and the family member or guardian having signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Excluding children with acute tonsillitis caused by other infections such as Mycoplasma pneumoniae and Chlamydia pneumoniae;(2) Children complicated with sepsis;(3) Children with pharyngeal symptoms or infections caused by diphtheria, scarlet fever, infectious mononucleosis pharyngitis, etc.;(4) Children complicated with severe primary diseases of the heart, liver, kidneys, digestive system, hematopoietic system, etc.;(5) Children who have developed severe complications, such as retropharyngeal abscess, parapharyngeal abscess, peritonsillar abscess, rheumatic fever, cardiac complications, etc.;(6) Children with a previous history of allergy to the study drug (amoxicillin sodium and clavulanate potassium). Key Notes on Terminology

Design outcomes

Primary

MeasureTime frame
Routine Blood Test;C-reactive protein;Procalcitonin (PCT);Interleukin-6 (IL-6);Erythrocyte Sedimentation Rate (ESR);Anti-Streptolysin O (ASO);—

Countries

China

Contacts

Public ContactDuan Yufeng

Huai'an Municipal Hospital of Traditional Chinese Medicine

845176244@qq.com+86 18762700267

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026